UBE2J2: A Potential Drug Target and Biomarker (G118424)

Target Name: UBE2J2

NCBI ID: G118424

UBE2J2

UBE2J2: A Potential Drug Target and Biomarker

Unearthing potential drug targets and biomarkers is a significant aspect of drug development. It involves identifying proteins that are involved in various physiological processes and diseases, and then using various techniques to study their functions to determine if they can be targeted with drugs. One such protein is UBE2J2, which has been identified as a potential drug target and biomarker for various diseases.

UBE2J2: The Unveiled Target

UBE2J2 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a member of the UBE2J family, which includes several similar proteins that are involved in various cellular processes. The UBE2J2 protein is known for its role in the regulation of mitochondrial function, and is involved in the production of energy in the form of ATP.

In addition to its role in energy production, UBE2J2 is also involved in the regulation of cellular processes that are critical for the survival and growth of cells. It plays a significant role in the development and maintenance of the blood-brain barrier, which is responsible for protecting the brain from harmful substances that could cause neurological damage. UBE2J2 is also involved in the regulation of cell death, which is a critical process that helps remove damaged cells from the body.

The Potential Drug Target

The discovery of UBE2J2 as a potential drug target is based on its involvement in the regulation of mitochondrial function and its role in the development and maintenance of the blood-brain barrier. Drugs that target UBE2J2 have the potential to treat various diseases, including cancer, neurodegenerative diseases, and sleep disorders.

One of the key advantages of targeting UBE2J2 is its potential to treat neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells, leading to a range of symptoms that can include cognitive decline, emotional instability, and difficulty with daily activities. Currently, there is no cure for these conditions, and drug development is focused on managing symptoms with existing treatments. Targeting UBE2J2 with drugs that enhance its function in the brain could potentially lead to new treatments for these conditions.

Another potential drug target for UBE2J2 is its role in the regulation of cell death. Cancer is a condition that is characterized by the uncontrolled growth and spread of cells. Drugs that target UBE2J2 have the potential to disrupt its role in cell death, leading to the inhibition of cancer cell growth.

The biomarker potential of UBE2J2 is its ability to serve as a marker for certain diseases, such as cancer. The blood-brain barrier is a critical barrier that separates the brain from the rest of the body, and its regulation by UBE2J2 is thought to be involved in the development and maintenance of this barrier. Drugs that target UBE2J2 could potentially be used to treat certain types of cancer, by enhancing the function of the blood-brain barrier and inhibiting the entry of cancer cells.

Conclusion

In conclusion, UBE2J2 is a protein that is involved in various cellular processes in the body, including energy production, cell death regulation, and blood-brain barrier development. Its potential as a drug target and biomarker makes it an attractive target for the development of new treatments for various diseases. Further research is needed to fully understand the functions of UBE2J2 and its potential as a drug target.

Protein Name: Ubiquitin Conjugating Enzyme E2 J2

Functions: Catalyzes the covalent attachment of ubiquitin to other proteins. Seems to function in the selective degradation of misfolded membrane proteins from the endoplasmic reticulum (ERAD)

The "UBE2J2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2J2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets